english.prescrire.org > Annual Prescrire Awards > The Prescrire Awards for 2022 > The Prescrire Drug Awards for 2022 > 2022 Drug Awards > Prescrire's ratings for new drugs and new indications

The Prescrire Awards for 2022

The Prescrire Drug Awards for 2022

The Prescrire Drug Awards for 2022
Prescrire's ratings for new drugs and new indications

PRESCRIRE'S RATINGS

Our judgement is based on the therapeutic advance of the product in the relevant clinical situation. It considers not only the inherent value of each product in terms of its harm-benefit balance, but also its advantages and disadvantages relative to existing treatments. Note that the relative value of new products can vary from one country to another.
 

Bravo

BRAVO

The product is a major therapeutic advance in an area where previously no treatment was available.

A Real Advance

A REAL ADVANCE

The product is an important therapeutic advance but has certain limitations.

Offers an advantage

OFFERS AN ADVANTAGE

The product has some value but does not fundamentally change current therapeutic practice.

Possibly helpful

POSSIBLY HELPFUL

The product has minimal additional value, and should not change prescribing habits except in rare circumstances.

Nothing new

NOTHING NEW

The product is a new substance but with no evidence that it has  more clinical value than other substances of the same group. It can be a me-too or a near me-too.

Not acceptable

NOT ACCEPTABLE

Product without evident benefit but with potential or real disadvantages.
 

Judgement reserved

JUDGEMENT RESERVED

The editors postpone their rating until better data and a more thorough evaluation of the product are available.

Le Palmarès de l'information
> The Prescrire Drug Awards for 2022


Download the full article:

Télécharger
 FREE  "The Prescrire Awards for 2022" Prescrire International 2023; 32 (246): 80-81. (pdf, free)

 

Back to "The Prescrire Awards for 2022">

©Prescrire March 2023
Share Share on Facebook Share on Twitter

Filet

Enjoy full access to Prescrire International, and support independent analysis